Radiation + Talquetamab for Extramedullary Disease
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedullary Disease
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 20 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Bispecific Antibody, Bispecific T Cell Engager (BiTE), CD3, GPRC5D, Radiation Therapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2006
- NCT Identifier
- NCT06572605
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.